Abstract Details

Title Seizure Control is not Associated With Obstructive Sleep Apnea in Adults With Epilepsy

Topic Sleep

Presentation(s) P9 - Poster Session 9 (5:00 PM-6:00 PM)

Poster/Presentation
Number 14-005

Objective

To examine associations between obstructive sleep apnea (OSA) severity and seizure frequency/severity in adults with epilepsy (AWE).

Background

OSA is among the most common comorbidities in AWE. Studies exploring the relationship between OSA measured by in-lab polysomnography (PSG) and seizure outcomes are conflicting and based on small samples.

Design/Methods

A total of 1048 AWE with completed PSG and the Liverpool Seizure Severity Scale (LSSS) were included. Seizure frequency was defined as the number of seizures excluding auras in the preceding 4 weeks. OSA was defined as having an apneas-hypopnea index (AHI) ≥5. AHI was categorized as no-OSA (<5), mild (5- <15), moderate: (15- <30), and severe (≥30) OSA. Categorical variables were compared using chi-square tests; continuous or ordinal variables with Wilcoxon or Kruskal-Wallis tests. Spearman correlations measured the association between AHI and LSSS severity.

Results Of 1,048 participants, 553 (52.8%) had OSA. Patients with OSA were older (50.1 ± 15.1 vs 42.9 ± 16.5 years, p<0.001), had higher BMI (33.9 ± 9.3 vs. 30.8 ± 8.1 kg/m2, p<0.001), and more likely to be male (40.9% vs. 28.5%, p<0.001) than those without OSA. Monthly seizure frequency in patients with OSA was 0.00 [0.00, 1.00] vs no-OSA 0.00 [0.00, 2.00] (p<0.64). LSSS score was 47.5 [35.0, 6.00] vs 51.3 [35.0, 67.5] in patients with OSA and no-OSA, respectively (p<0.47). Seizure frequency and LSSS scores did not differ by AHI category (p=0.41/0.53, respectively). No correlation between AHI and LSSS was found [ρ = -0.10 (-0.24, 0.05), p=0.20].

Conclusions

In this largest, single-center cohort of AWE with PSG, OSA was associated with age, BMI and gender as seen in the general population, but not with seizure frequency or severity. Given the known adverse health outcomes of untreated OSA, screening should be considered in all AWE regardless of seizure control.

Authors/Disclosures
Tyler Bare, MD PRESENTER	Dr. Bare has nothing to disclose.
Jad El Ahdab, MD	Dr. El Ahdab has nothing to disclose.
Nancy R. Foldvary-Schaefer, DO, FAAN (Cleveland Clinic)	Dr. Foldvary-Schaefer has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Suven. The institution of Dr. Foldvary-Schaefer has received research support from Takeda. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care.
James Bena, MS	Mr. Bena has nothing to disclose.
Delaney Ryan, MPH	Miss Ryan has nothing to disclose.
Matheus Lima Diniz Araujo, PhD	Dr. Lima Diniz Araujo has nothing to disclose.
Madeleine M. Grigg-Damberger, MD (University of New Mexico, Department of Neurology)	Dr. Grigg-Damberger has received personal compensation for serving as an employee of Oxford University Press. Dr. Grigg-Damberger has received personal compensation for serving as an employee of Up-to-date. Dr. Grigg-Damberger has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Sleep Medicine. Dr. Grigg-Damberger has received publishing royalties from a publication relating to health care.
Sikawat Thanaviratananich, MD (Case Western Reserve University)	Dr. Thanaviratananich has nothing to disclose.

��ɫ��

��ɫ��